Showing 7 posts of 52 posts found.

Forest depression candidate struggles against placebo

March 1, 2011
Research and Development Forest, Forest Laboratories, Gedeon Richter, cariprazine, depression, major depressive disorder

An investigational antipsychotic drug being developed by Forest Laboratories and Budapest-based Gedeon Richter has failed to prove itself in phase …

AZ-Targacept depression candidate moves into phase IIb

February 9, 2011
Research and Development AZ, AstraZeneca, TC-5214, Targacept, depression, major depressive disorder

AstraZeneca and Targacept have begun a phase IIb trial of TC-5214 as a ‘switch’ monotherapy for patients with depression. The …

PHQ screeners site

Digital Pharma: Pfizer puts mental health diagnosis tools online

July 26, 2010
Medical Communications Digital Pharma blog, Pfizer, depression, digital patients

Pfizer has put two widely used mental health assessment tools online for the public to use. It aims to improve …

AstraZeneca and Targacept begin depression trials

June 24, 2010
Research and Development AstraZeneca, Targacept, depression

AstraZeneca and Targacept have begun enrolling patients in phase III trials for TC-5214, a new treatment for depression. The new …

GSK agrees generic deal on Malarone

April 13, 2010
Sales and Marketing GSK, depression, generics

Generic versions of two GlaxoSmithKline products have received the green light for launch in the US. Mylan has been given …


AZ licences late-stage depression candidate

December 8, 2009
Sales and Marketing AZ, Targacept, depression

AstraZeneca is to pay $200 million up front for rights to a late-stage developmental drug aimed at sufferers from depression …

Wyeth pulls European application for Ellefore

October 16, 2008
Sales and Marketing EU, Pfizer, depression

The European future of Wyeth’s depression treatment Ellefore has been thrown into doubt after the pharma company withdrew its application …

Latest content